Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Membrane translocation and activation of GnRH receptor sensitize prostate cancer cells to radiation
Indexado
WoS WOS:000700483200001
Scopus SCOPUS_ID:85115754464
DOI 10.1080/09553002.2021.1980628
Año 2021
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Background GnRH analogs are widely used as neoadjuvant agents for radiotherapy in prostate cancer (PCa) patients, with well-documented effects in reducing tumor bulk and increasing progression-free survival. GnRH analogs act locally in the prostate by triggering apoptosis of PCa cells via activation of the GnRH receptor (GnRHR). During PCa progression, the distribution of GnRHR within the cell is altered, with reduced expression in the cell membrane and remaining sequestered in the endoplasmic reticulum. Pharmacoperone IN3 is able to relocalize GnRHR to the cell membrane. The aim of this study was to evaluate the effect of radiation on PCa cells pretreated with leuprolide, alone or in combination with IN3, as radiosensitizers. Material and methods PC3 and human PCa primary cell cultures were treated with IN3 for 24 h, followed by different doses of leuprolide for 48 h and, finally, single doses of radiation (3, 6, and 9 Gy). After radiation, cell survival, apoptosis, cell cycle distribution, and colony growth were evaluated. Results Radiation reduced cell survival and increased apoptosis in a dose-dependent manner. This effect was also directly related to leuprolide concentration. Pretreatment with IN3 enhanced apoptosis and decreased cell survival, also observing a higher proportion of cells arrested in G2. Conclusion Neoadjuvant leuprolide increases radiation-mediated apoptosis of PCa cells. This effect was enhanced by pretreatment with pharmacoperone IN3. Clinical use of IN3 as a radiosensitizer combined with androgen deprivation therapy to improve survival of patients with PCa remains to be evaluated.

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Biology
Radiology, Nuclear Medicine & Medical Imaging
Nuclear Science & Technology
Scopus
Radiology, Nuclear Medicine And Imaging
Radiological And Ultrasound Technology
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 SANCHEZ-NUNEZ, CATHERINE ANDREA Mujer Clínica Las Condes - Chile
2 MERCADO-CAMPERO, ALEJANDRO JOSE Hombre Clínica Las Condes - Chile
Universidad de Chile - Chile
3 CONTRERAS-MUNOZ, HECTOR RUBERLY Hombre Universidad de Chile - Chile
4 Carvajal, Felipe Hombre Universidad de Chile - Chile
5 SALGADO-FERNANDEZ, APOLO HOMERO - Instituto Nacional del Cancer - Chile
Instituto Nacional del Cáncer, Chile - Chile
6 HUIDOBRO-ALVARADO, CHRISTIAN CARLOS Hombre Clínica Las Condes - Chile
7 CASTELLON-VERA, ENRIQUE ALEJANDRO Hombre Universidad de Chile - Chile

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Fondo Nacional de Desarrollo Científico y Tecnológico
National Cancer Institute
Merck Sharp and Dohme
Agencia Nacional de Investigación y Desarrollo
Fondo Nacional de Desarrollo Cientifico y Tecnologico (Fondecyt, ANID), Chile

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
This study was supported by Grant N<SUP>circle</SUP> 3090016 and 11121525 (C. Sanchez) and N<SUP>circle</SUP> 1140417 (E. Castellon) from Fondo Nacional de Desarrollo Cientifico y Tecnologico (Fondecyt, ANID), Chile. Pharmacoperone IN3, was provided under agreement by Merck Sharp & Dohme Corp (New Jersey, USA).
This study was supported by Grant N° 3090016 and 11121525 (C. Sánchez) and N° 1140417 (E. Castellón) from Fondo Nacional de Desarrollo Científico y Tecnológico (Fondecyt, ANID), Chile. Pharmacoperone IN3, was provided under agreement by Merck Sharp & Dohme Corp (New Jersey, USA). Thanks to miss Graciela Caroca for her excellent technical assistance and Martín Mondaca, Pamela Poblete, Nelson Rocha and Jorge Corvalán from the Radiation Oncology Service of the National Cancer Institute for their support and willingness.

Muestra la fuente de financiamiento declarada en la publicación.